



(12) **United States Patent**
Bartholomaeus et al.

(10) **Patent No.:** **US 9,675,610 B2**
(45) **Date of Patent:** ***Jun. 13, 2017**

- (54) **ABUSE-PROOFED DOSAGE FORM**
- (71) Applicant: **GRÜNENTHAL GMBH**, Aachen (DE)
- (72) Inventors: **Johannes Bartholomaeus**, Aachen (DE); **Heinrich Kugelmann**, Aachen (DE)
- (73) Assignee: **GRÜNENTHAL GMBH**, Aachen (DE)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **15/245,424**
- (22) Filed: **Aug. 24, 2016**
- (65) **Prior Publication Data**
US 2016/0361306 A1 Dec. 15, 2016

Related U.S. Application Data

- (60) Continuation of application No. 14/527,911, filed on Oct. 30, 2014, now abandoned, which is a continuation of application No. 14/069,439, filed on Nov. 1, 2013, now abandoned, which is a continuation of application No. 13/803,789, filed on Mar. 14, 2013, now abandoned, which is a continuation of application No. 13/572,926, filed on Aug. 13, 2012, now abandoned, which is a continuation of application No. 13/365,742, filed on Feb. 3, 2012, now abandoned, which is a continuation of application No. 12/822,719, filed on Jun. 24, 2010, now abandoned, which is a division of application No. 11/007,887, filed on Dec. 9, 2004, now Pat. No. 7,776,314, which is a continuation-in-part of application No. PCT/EP03/06314, filed on Jun. 16, 2003.

(30) **Foreign Application Priority Data**

Jun. 17, 2002 (DE) 102 27 077
Oct. 25, 2002 (DE) 102 50 083

(51) **Int. Cl.**

A61K 31/485 (2006.01)
A61K 9/20 (2006.01)
A61K 9/48 (2006.01)
A61K 31/137 (2006.01)
A61K 31/5513 (2006.01)
A61K 45/06 (2006.01)
A61K 47/38 (2006.01)
A61K 9/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/485** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/205** (2013.01); **A61K 9/2054** (2013.01); **A61K 9/4866** (2013.01); **A61K 31/137** (2013.01); **A61K 31/5513** (2013.01); **A61K 45/06** (2013.01); **A61K 47/38** (2013.01)

- (58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,524,855	A	10/1950	Schnider et al.
2,806,033	A	9/1957	Lewenstein et al.
2,987,445	A	6/1961	Levesque
3,332,950	A	7/1967	Blumberg et al.
3,370,035	A	2/1968	Ogura et al.
3,652,589	A	3/1972	Flick et al.
3,806,603	A	4/1974	Gaunt et al.
3,865,108	A	2/1975	Hartop
3,941,865	A	3/1976	Miller et al.
3,966,747	A	6/1976	Monkovic et al.
3,980,766	A	9/1976	Shaw et al.
4,002,173	A	1/1977	Manning et al.
4,014,965	A	3/1977	Stube et al.
4,070,494	A	1/1978	Hoffmeister et al.
4,070,497	A	1/1978	Wismer et al.
4,175,119	A	11/1979	Porter
4,200,704	A	4/1980	Stanley et al.
4,207,893	A	6/1980	Michaels
4,262,017	A	4/1981	Kuipers et al.
4,343,789	A	8/1982	Kawata et al.
4,353,887	A	10/1982	Hess et al.
4,404,183	A	9/1983	Kawata et al.
4,427,681	A	1/1984	Munshi et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AR	046994	A1	12/2004
AR	045353	A1	10/2005

(Continued)

OTHER PUBLICATIONS

2.9 Methoden der pharmazeutischen Technologie, European Pharmacopeia, 143-144, 1997. (Full English translation attached).

(Continued)

Primary Examiner — Jessica Worsham

(74) *Attorney, Agent, or Firm* — Norris McLaughlin & Marcus, P.A.

(57) **ABSTRACT**

A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

20 Claims, No Drawings